BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8514614)

  • 1. Pharmacokinetic evaluation of (glycolato-O,O')diammine platinum(II) in lung lymph in sheep.
    Koizumi T; Kubo K; Shinozaki S; Koyama S; Amari T; Hayano T; Fujimoto K; Kobayashi T; Sekiguchi M; Sakai R
    Jpn J Cancer Res; 1993 Apr; 84(4):468-73. PubMed ID: 8514614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
    Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
    Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
    Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
    Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
    Ota K; Oguma T; Shimamura K
    Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs.
    Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.
    Takahashi I; Maehara Y; Kusumoto H; Kohnoe S; Sugimachi K
    Cancer Chemother Pharmacol; 1993; 33(1):31-5. PubMed ID: 8269586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding?
    LeRoy AF; Thompson WC
    J Natl Cancer Inst; 1989 Mar; 81(6):427-36. PubMed ID: 2918550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of platinum following the administration of cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in dogs.
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1997; 17(5A):3681-3. PubMed ID: 9413223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
    Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
    Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of new cisplatin analogues in experimental animals].
    Fujita H; Okamoto M; Takao A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1366-72. PubMed ID: 2658824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile].
    Hirabayashi K; Okada E; Oguma T; Shimamura K
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2221-7. PubMed ID: 2241186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
    Kim HT; Kim DK; Cho YB; Kim TS; Jung I; Kim KH; Heo DS; Bang YJ; Shin SG; Kim NK
    Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
    Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
    Los G; Mutsaers PH; Ruevekamp M; McVie JG
    Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of a cisplatin-chondroitin sulfate A complex in plasma and kidney in terms of protein binding.
    Zhang JS; Shen-Feng MA; Suenaga A; Otagiri M
    Biol Pharm Bull; 2001 Aug; 24(8):970-2. PubMed ID: 11510498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological approach to the platinum compounds].
    Sasaki Y
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.